Christopher McNulty

Chris joined Ring Therapeutics as Chief Financial Officer, Head of Corporate Strategy in May 2023. He brings over 15 years of business and corporate finance experience in the pharmaceutical and biotech sector to the team. He joins Ring from VBI Vaccines, where he led the finance and business development teams as CFO and Head of Business Development. Previously, he held multiple executive roles at InVivo Therapeutics, including CFO, where he led the finance efforts for over $50 million of financing. Prior to InVivo Therapeutics, Chris held a Director and Senior Director role at Repligen Corporation, where he was responsible for in-licensing and out-licensing activities that resulted in a deal with Biomarin. Additionally, he held various director-level positions at Seventh Sense Biosystems, where he secured $3.3M in funding and Genzyme Corporation, where he led two collaborations in the rare genetic disease space. Chris graduated with a B.S. and master’s degree in electrical engineering & computer science from MIT and received a master’s in business administration from Harvard Business School.